Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis
NCT07550673Phase 4Recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in ulcerative colitis (UC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Clinical response by day 7. Started Apr 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07550673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550673.